RUSSELL P. KRUZELOCK Curriculum Vit e

***** ****** *****

Helotes, TX 78023

210-***-****

abkppq@r.postjobfree.com

EDUCATION:

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER

M.D. ANDERSON CANCER CENTER

Department of Molecular Genetics

Houston, TX

Doctor of Philosophy, Genetics

(Completion date: August, 1995)

Dissertation Research: "Mitotic Mapping of a Novel Tumor

Suppressor Locus on

Human Chromosome 3q Important in

Osteosarcoma Tumorigenesis"

Dissertation Advisor: Dr.

Marc F. Hansen

Major Subjects: Molecular & Cellular Approaches to Human

Genetics, Eukaryotic Gene Expression

Minor Subjects: Biochemistry,

Developmental Biology

Achievements: NIH Training Grant Recipient (1992-1994); American

Legion Fellowship Recipient (1995)

GSBS Graduate Student Association (GSA) President (1992-1993)

THE PENNSYLVANIA STATE UNIVERSITY

Department of Genetics

Department of Poultry Science

University Park, PA

Master of Science, Genetics

(Completion date: May, 1991)

Thesis Research: "The Genetic Architecture of

Imprinting in Chickens"

Thesis Advisor:

Dr. Guy F. Barbato

Major Subjects: Population Genetics, Ecological Genetics,

Animal Genetics, Plant Breeding,

Microbial/Molecular Genetics

Minor Subjects: Statistics: Regression Analysis, Analysis of

Variance, Experimental Design,

Vertebrate Neuroanatomy, Animal Physiology

Achievements: Graduate Student Association (GSA)

Representative (1989-1990)

THE PENNSYLVANIA STATE UNIVERSITY

Department of Biology

University Park, PA

Bachelor of Science, Biology

Vertebrate Physiology

(Completion date: May, 1987)

Major Subjects: Mammalian Physiology, Vertebrate Anatomy,

Endocrinology, Gerontology, Embryology

Minor Subjects: Organic Chemistry, Biochemistry,

Microbiology, Statistics, Genetics

Achievements: $14,000 Heublein Foundation Competitive Grant received for

academic & extracurricular achievements.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 2)

EMPLOYMENT EXPERIENCE:

3/07 to Present

CENOVANCE, LLC

TEXAS RESEARCH PARK

San Antonio, Texas

President

Cenovance,LLC meets an urgent need for independent and objective analysis

of technologies that have potential value to US and Coalition partners.

This support includes the management of new capabilities having commercial

applications. Active initiatives include:

Renewable Resources:

? Biofuel Energy Testing Training & Evaluation Resource (BETTER)

? Renewable Energy Field Development Facility (REFD)

? Parasitic Sensor Power: Perpetual Power for Sensor Buoys (PSP)

? Scalable Electro-Dialysis Desalination: A Viable Alternative to

NSRO (EDD)

Biomedicine:

? Pandemic Influenza Surveillance: Rapid Influenza H&N Identification

& Sequencing (FLU)

? Tissue Typing Microarray: Rapid Tissue Typing; Personal DNA ID;

Vaccine Response (TTMA)

? Prevention of Inadvertent Needlestick Injuries (PINI)

? Metafactor Omni-Coach Weight Management Program (WMP)

? VeinViewer: Field Vein Visualization for Reducing Battlefield

Mortality (VV)

Intelligence & Communications:

? Requirements Road-Mapping Distributed Database (R2D2)

? Manufacturing Opportunity Matching Database (MOM)

? Iridium-based Blue Force Tracking (IBFT)

? Robust Battlefield Wireless Network (RBWN)

? Associative Learning Based Electronic Recognition Technology

(ALBERT)

? Operational Management Process Portal: Managing Transition for New

Capabilities (OMP2)

? Threat Assessment Dashboard (THAD)

Force Protection:

? Center for Ballistic and Advanced Armor Materials (C-BAAM)

? High Resolution Seismic Reflectomety For Tunnel Detection (HRSR)

? Sniper Avoidance Fabric Enclosure (SAFE)

? AR-3Ten Carbine Single Platform Rifle; Shotgun; Subgun (AR-3Ten)

? 338 Lapua Semi-automatic Precision Sniper Rifle (.338 PSR)

? Bulleted-Shotshell Rifle Ammunition: For Active RPG Defeat (BSRA)

? Shotscreen RPG Defeat System for Medical Helicopter RPG Protection

(SHOTSCREEN)

? Engine Performance Enhancement for NSCVs (EPE)

? Flashless Precision Ammunition Plant (FPA)

? Lightweight Improved Ballistic Armor for Medical Helicopter RPG

Protection (LIBA RPG)

? Light Improved Ballistic Armor Indoor Ballistic Wall (LIBA BW)

? Lightweight Improved Ballistic Armor for HMMWVs (LIBA HMMWV)

? Advanced Gun Barrel Capability: Polymer Plating for Improved Gun

Ballistic Characteristics (AGBC)

Spin-off Companies:

? Melanosight: Tools for Personal Melanoma Surveillance

? T2 Foundation: Economic Development for New England Technology

Corridor [MOM Database]

? Neutra-Energy: Renewable Oil & Biofuel Production

? ezStandards: Controls & Standards for Biotech Research &

Development Laboratories

? Perun Security Systems: Unconditionally secure cyber, network and

communication security

? Dynamic Technology Solutions: reclaiming waste and reducing

hazardous waste liability.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 3)

EMPLOYMENT EXPERIENCE CONTINUED:

3/07 to 3/08 TEXAS RESEARCH AND TECHNOLOGY

FOUNDATION

TEXAS RESEARCH PARK

San Antonio, Texas

Executive Director

Institute for Technology Transformation

The Institute for Technology Transformation works to stimulate economic

growth in South Central Texas through the development of incentive programs

that improve the attractiveness of San Antonio as an incubator for emerging

high-tech industry. Active programs include:

? Finalist for National Biologic and Agricultural Defense Facility -

$600 million DHS Contract

? Greehey Biotechnology Accelerator Facility (GBAF) - South Texas

Medical Center

? McDermott Pre-Seed Economic Development Fund

? Rapid Mobilization of Manufacturing Resources for the Defense

Logistics Agency (DLA)

? Training Program Improving Accessibility to High-Quality Technical

Data Packages

? Public database repository of technologies that can be searched and

evaluated

6/04 to 4/07 CANCER THERAPY & RESEARCH CENTER: INSTITUTE FOR DRUG

DEVELOPMENT

TEXAS RESEARCH PARK

San Antonio, Texas

Department Head

Department of Pharmacogenomics

Identify predictive molecular markers that when integrated with clinical

signs, symptoms, tests and outcomes, permits a more informed approach to

cancer drug development and an individualized approach to cancer therapy.

Helped the IDD reach international status as the premier phase 1 cancer

research program in the world.

? Establish new translational research programs related to anticancer

drug development

? Develop an integrated pharmacogenomic strategy that supports

preclinical antitumor efficacy models

? Create standards that permit better reproducibility and integration

of biomarker data

? Develop collection, processing and analysis protocols, and a

database for a tumor tissue repository

? Improve molecular characterization of in vitro & in vivo

preclinical models used in drug development

? Create web-based bioinformatics platforms that permit data

mining for hypothesis generation and testing.

? Build high-throughput cancer molecular profiling capabilities

including:

? Mutation Screening

? High-density SNP Genotyping

? Genome-wide Loss of Heterozygosity

? Gene Expression Profiling

5/04 to 6/07

MDANGEL, LLP

TEXAS RESEARCH PARK

San Antonio, Texas

President

MDAngel is a Translational Research Organization that specializes in

integrating bioinformatics and biomarker services for improved early phase

clinical trial design and results.

Areas of specialization include:

? Biomarker Discovery

? Centralized Pharmacogenomics Laboratory testing services:

? Clinical trials - Phase 1 and Phase 2 oncology trials

? Pre-Clinical trials - In vitro and in vivo mouse xenograft tumor

models

? R&D Services - Genomic biomarker development and validation

? Project management - from pre-study consultancy to professional

assistance and on-site training

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 4)

EMPLOYMENT EXPERIENCE CONTINUED:

6/02 to 6/04 UNITED STATES AIR FORCE, OFFICE OF THE SURGEON

GENERAL

BOLLING AIR FORCE BASE

Washington D.C.

Scientific Advisor (IPA)

Team Leader, Epidemic Outbreak Surveillance (EOS) Project

LACKLAND AIR FORCE BASE & BROOKS CITY BASE

San Antonio, Texas

Director, United States Air Force Advanced Diagnostics Research

Laboratories

Scientific Advisor (IPA): Epidemic Outbreak Surveillance Program.

? Assessed new biodefense technologies for the Air Force, Navy and

Homeland Security

? Invented new technologies that improve infectious disease

surveillance infrastructure

? Co-developed the Air Force Medical Services (AFMS) biodefense

modernization strategy.

? Over 88 million dollars raised for Epidemic Outbreak Surveillance

research and program funding.

? Provided AFMS leadership for matters relating to pathogen

identification (including SARS outbreak)

? Developed & evaluating military operational requirements relating

to biosurveillance and biodefense

? Developed automated algorithms that rapidly detect an infectious

disease outbreak.

? Established electronic data element standards for microarray

testing.

? Co-developed bioinformatics tools for the integration of molecular

technologies.

? USAF liaison establishing collaborative research with government &

civilian agencies

? Member of the Epidemic Outbreak Surveillance Program Operational

Board

Director: United States Air Force Advanced Diagnostics Research

Laboratories.

? Directed research from three pathogen laboratory facilities at

Lackland & Brooks AFB.

? Designed & supervised construction of an additional 3000 sq. ft

diagnostic research laboratory.

? Designed mobile and deployable environmental surveillance

laboratory facilities.

? Established a repository of clinical, and molecular data relating

to infectious disease outbreaks.

? Integrated laboratory and clinical data with real-time pathogen

identification technologies.

? Designed & built a pathogen microarray for the detection of URIs

and agents of bioterrorism.

? Identified novel biomarkers for upper respiratory infections (URIs)

and biothreat agent exposure.

? Determined the positive predictive value of microarrays for

detecting respiratory pathogens (URIs).

? Maximized the reproducibility of gene expression profiling for high-

throughput production analysis.

? Developed a LIMS system / guidelines for quality laboratory data

collection and analysis.

? Integrated GLP infrastructure for rapid diagnostic approval by the

FDA.

6/01 to 6/02 VIRGINIA BIOINFORMATICS INSTITUTE (VIRGINIA TECH

UNIVERSITY)

Blacksburg, Virginia

Research Assistant Professor

? Principle Investigator & Director of the Virginia Bioinformatics

Institute microarray core facility.

? Associate Director of Horseshoe Crab Research Center, Virginia

Tech.

? Over 25 million dollars raised for cancer and biodefense-related

research.

? Developed the model for a Pathogen Information Repository for a

National Biodefense Initiative.

? Developed a system to predict pre-symptomatic individuals most at

risk for developing lung cancer.

? Developed novel gene expression profiling systems using nanocrystal

technologies.

? Developed a recombinant endotoxin assay based upon Limulus

amoebocyte clotting cascade.

? Created an oligonucleotide-based microarray system to examine

alternative splicing.

? Utilized a high-throughput functional assay to characterize genes

that alter cancer growth potential.

? Developed custom pathogen arrays for Brucella and Malaria and

host/vector arrays.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 5)

EMPLOYMENT EXPERIENCE CONTINUED:

8/98 to 5/01 HOWARD HUGHES MEDICAL INSTITUTE (BAYLOR COLLEGE OF

MEDICINE)

Houston, Texas

Associate - Dr. Allan Bradley

? Developed a new "liquid array" technology for gene expression

profiles.

? Constructed and optimized a 10,000 gene sequence verified murine

expression microarray.

? Constructed a series of deletions on mouse chromosome 11 to

identify novel tumor suppressor loci.

? Created series of mouse chromosome 11 germline mutations in genes

important in development.

? Developed novel microarray applications (ie. a primer extension

protocol for polymorphism detection).

? Developed sequence verified, size selected mouse cDNA Libraries.

? Baylor College of Medicine Microarray Technology Advisory Board

Member

8/95 to 8/98 THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER

CENTER,

Houston, Texas

Postdoctoral Fellow - Dr. Robert C. Bast

? Localized a novel tumor suppressor locus on chromosome 22 important

in ovarian cancer.

? Developed an in vitro 48-96 hour tumor suppressor selection assay

using a lipophilic stain and fluorescence activated cell sorting.

? Developed a Yeast Artificial Chromosome (YAC) fusion assay to

identify novel tumor suppressor loci important in ovarian tumor

progression.

? Established a connection between the retinoblastoma gene (RB1)

expression and telomerase activity.

? Investigated the role of the VHL gene in renal cell carcinoma

tumorigenesis.

8/90 to 8/95 THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER

CENTER,

Houston, Texas

Predoctoral Fellow - Dr. Edwin C. Murphy, Jr.

? Localized a novel tumor suppressor locus important in osteosarcoma

tumorigenesis.

? Assisted in the management of M.D. Anderson's osteosarcoma tumor

bank in collaboration with Dr. Marc Hansen and Dr. Louise Strong.

? Searched for a homologue of the retinoblastoma gene (RB1) in

Aspergillus Nidulans.

? Funded majority of research through an NIH Training Grant and an

American Legion Fellowship.

8/88 to 8/90 THE PENNSYLVANIA STATE

UNIVERSITY,

University Park, Penna.

Graduate Research Assistant - Dr. Guy F. Barbato

? Demonstrated genetic differences in catecholamine concentrations in

the hypothalamus, optic tectum, and hyperstriatum ventrale in

neonate Gallus gallus domesticus chicks.

? Determined significant heterosis for catecholamine concentration

between three lines of Gallus gallus domesticus using a full

diallele cross.

? Assisted in the isolation of a vasoactive peptide from cardiac

tissue of Gallus gallus domesticus.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 6)

EMPLOYMENT EXPERIENCE CONTINUED:

7/87 to 5/88 THOMAS C. SNADER

CONSULTANTS INC.,

Doylestown, Penna.

Research Associate - Dr. Thomas C. Snader

? Scheduled and supervised research assistants gathering

pharmaceutical products marketing data.

? Developed procedures to gather pharmaceutical marketing data.

? Established a national nursing home drug audit to rank drugs by

manufacturer and usage in the long-term care community. (150,000

bed data base) This included defining parameters for related

proprietary software programming.

? Developed, planned and budgeted new research programs.

? Interviewed and trained new research associates in drug research

procedures.

? Planned, coordinated and conducted medical seminars for nurses,

doctors and pharmacists.

9/85 to 6/87 PENN STATE MEDICINE HEALTH AND AGING RESEARCH

PROJECT

University Park, Penna.

Voluntary Research Assistant - Dr. Daniel Lago

? Research assistant to Doctors Lago, Smyer, and Ahern. I

volunteered for this work to gain first hand research experience

while attending college.

? Performed data analysis and literature reviews. First Author "The

Prevalence of Concurrent Use of Anticholinergic Drugs in Elderly."

I presented this paper at the Gerontological Society of America

convention in Washington D.C. (November, 1987).

RECENT FUNDING:

NSWC - Crane, Department of Defense (PI) $831,208

09/1/10 - 08/31/15

Non-Traditional Assessment: Identify, independently assess, and transition

new capabilities for government venues. Our organization focuses on

rapidly identifying and proving the worth of innovative and revolutionary

operations and logistics concepts. The resulting efforts provide the DoD

opportunities to reach investment decisions more quickly by helping to

organize, train, equip, and program, more effectively. (Funding Pending)

NSWC - Crane, Department of Defense (PI) $250,000

01/18/08 - 09/30/09

Joint Innovation & Technology Transition Center: There is an urgent need

for rapid assessment services that provide independent and objective

analysis results and findings on technologies that have the potential value

to US and Coalition partners to defend against asymmetric threats

associated with the Global War On Terrorism (GWOT).

CDRMP, Department of Defense (Co-PI) $1,000,000

09/01/06 - 08/31/07

Center for Targeted Therapy & Biomarker Discovery: Collaborative program

between the Cancer Therapy and Research Center (CTRC) and Brooke Army

Medical Center (BAMC) to establish and develop pharmacogenomics and

bioinformatics infrastructure for a cancer biomarker discovery program.

United States Air Force, Force Protection Battlelab (PI) $155,682

09/01/04 - 08/31/05

Tissue Typing Microarray: Design and Validation of an Affymetrix CustomSeq

HLA typing microarray for combined high-resolution tissue-typing and

pathogen identification.

Cancer Center Council (PI) $22,500 6/1/05-

5/31/06

Drug Metabolism Polymorphisms for Assessing Therapeutic Response in Cancer:

Development of sequencing based assays to screen for CYP450 SNPs that may

contribute to therapeutic response and cancer drug toxicity.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 7)

RECENT FUNDING CONTINUED:

San Antonio Area Foundation (PI) $20,000 6/1/05-

5/31/06

Custom Colorectal Cancer Microarray: Design and Validation of an

Affymetrix CustomSeq Microarray that sequences important drug targets and

pathways identified as major targets for cancer progression and drug

development.

Deputy Undersecretary of Defense AS&C, (Co-PI) $88,000,000

08/01/03 - 07/31/09

Advanced Concepts Testing Demonstrator: Epidemic Outbreak Surveillance

Program: A national biodefense program to more quickly identify,

characterize and respond to infectious disease outbreaks in response to

Anthrax contaminations in 2002.

United States Air Force Medical Services (Co-PI) $500,000

08/01/03 - 02/28/05

Epidemic Outbreak Surveillance Program: Design, manufacture and validation

of an advanced prototype Respiratory Pathogen Microarray (including SARS).

United States Air Force Medical Services (Co-PI) $800,000

08/01/03 - 07/31/04

Epidemic Outbreak Surveillance Program: Establishing baseline

microarray biosignatures to better distinguish immunologic response

patterns associated with exposure to respiratory tract infections.

United States Air Force Medical Services (Co-PI) $1,200,000

08/01/03 - 07/31/04

Epidemic Outbreak Surveillance Program: Funding allocated for the

design and construction of a 3338 sq. ft. Advanced Diagnostics Research

Laboratory.

Defense Threat Reduction Agency (DTRA) (Co-PI) $6,000,000

06/25/02 - 06/24/04

Epidemic Outbreak Surveillance Project: Proof-of-concept funding to develop

improved diagnostic markers for infectious diseases that are critical to

our national defense initiative.

SBCCOM, U.S. Army, Department of Defense (PI) $4,500,000

04/01/02 - 03/31/04

Common Asset for Biological Security - A database storing and organizing

known pathogens and their near relatives.

National Science Foundation (Co-PI) $6,764,465

10/01/02 - 09/30/07

Dissecting Soybean Resistance to Phytophthera by QTL Analysis of Host and

Pathogen Expression Profiles.

Tobacco Commission (Co-PI) $4,000,000

06/01/02 - 05/30/03

Collaborative Proposal: Identification of Genes that Predispose Individuals

to Smoking-related Diseases $399,154

Virginia Tech Foundation/ Johns Hopkins Univ (Co-PI) $10,000,000

02/01/02 - 01/31/03

A Candidate Gene Approach for the Discovery and Analysis of Genes

influencing Malaria Transmission $381,500

American Cancer Society-IRG (PI) $16,905

09/01/01 - 06/01/02

Development of Fluid-based Microarray Technology Using Microspheres and

Quantum Dots

Aspires Grant (Virginia Tech) (Co-PI) $17,537

01/01/02 - 12/31/02

Open Gene-Xpediter an Upload tool for Gene Expression Data

HATCH Foundation Grant (PI) $18,000 09/01/02 -

08/31/05

A Cytokine Microsphere Array, an Improved Platform for Gene Expression

Profiling

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 8)

PUBLICATIONS & REVIEWS:

1. Kruzelock, R., Lago, D., Rabatin, V., Roberts, J., and Ahern, F.

(1991). Prevalence of Concurrent Use of Anticholinergic Drugs in a

Geriatric Pharmaceutical Assistance Program. Journal of Geriatric Drug

Therapy, 5(1), 41-54.

2. Kruzelock, R.P., and Barbato, G.F. (1991). Genotype Differences in

Catecholamine Concentrations in the Hypothalamus, Intramedial

Hyperstriatum Ventrale, and Optic Tectum of Newly Hatched Chicks.

Neurochemical Research, 16(2), 105-112.

3. Barbato, G.F., and Kruzelock, R.P. (1992). Heterosis for Catecholamine

Concentrations in the Chick Hypothalamus, Intramedial Hyperstriatum

Ventrale, and Optic Tectum. Behavior Genetics, 22(3), 381-398.

4. Kruzelock, R.P., and Hansen, M.F., (1995). The Molecular and

Cytogenetics of Sarcomas. Hematology/Oncology Clinics of North

America: W.B. Saunders Company, Philadelphia, 9(3), 513-539.

5. Kruzelock, R.P., Murphy E.C., Strong, L.C., Naylor, S.L., and Hansen,

M.F. (1997). Localization of a Novel Tumor Suppressor Locus on

Chromosome 3q Important in Osteosarcoma Tumorigenesis. Cancer

Research, 57, 106-109.

6. Xu, H-J., Zhou, Y., Wan, J., Perng, G-S., Kruzelock, R.P., Cheng-Te,

K., Bast, R.C., Mills, G.B., Li, J., and Hu, S-X. (1997). Reexpression

of the Retinoblastoma Protein in Tumor Cells Induces Senescence and

Telomerase Inhibition. Oncogene, 15, 2589-2596.

7. Kruzelock, R.P., Wiener, J.R. and Mills, G.B. (1997). Human Cancer

Genetics: Science Fiction Becomes Science Fact. Breast Diseases: A

Year Book Quarterly, 8(1), 15-19.

8. Wiener, J. R., Nakano, K., Bucana, C., Kruzelock, R. P., Bast, R.C.

Jr., and Gallick, G.E. (1999). Decreased c-src Tyrosine Kinase

Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a

Nude Mouse Model. Clinicial Cancer Research, 5(8), 2164-2170.

9. Kruzelock, R.P., Cuevas, B.D., Xu, F., Yu, Y., Lovell, M., Killary,

A.M., Mills, G.B., and Bast, R.C. (2000). Functional Evidence for an

Ovarian Cancer Tumor Suppressor Gene on Chromosome 22 by Microcell-

mediated Chromosome Transfer. Oncogene, 19(54), 6277-6285.

10. Thach, D.C., Lin B., Walter E., Kruzelock R.P., Stenger, D.A. (2003).

Assessment of two methods for handling blood in PAXgeneTM RNA tubes

for surveillance of gene expression profiles with the Affymetrix

Genechip system. Journal of Immunological Methods, 283(1-2), 269-79.

11. Daum, L.T., Ye K, Chambers, J.P., Santiago J., Hickman, J.R., Barnes,

W.J., Kruzelock, R.P., Atchley, D.H. (2004). Comparison of TaqMan

trade mark and Epoch Dark Quenchers trade mark during real-time

reverse transcription PCR. Mol Cell Probes, 18(3), 207-9.

12. Lin B., Wang Z., Vora G.J., Thornton J.A., Schnur J.M., Thach D.C.,

Blaney K.M., Ligler A.G., Malanoski A.P., Santiago J., Walter E.A.,

Agan B.K., Metzgar D., Seto D., Daum L.T., Kruzelock R.P., Rowley

R.K., Hanson E.H., Tibbetts C., Stenger D.A. (2006). Broad-spectrum

respiratory tract pathogen identification using resequencing DNA

microarrays. Genome Research 16(4), 527-35.

13. Karmaker, A., Yoon, K., Doderer, M., Kruzelock, RP., Kwek, S. (2007).

Identifying Transcription Regulatory Elements in the Human and Mouse

Genomes Using Tissue-Specific Gene Expression Profiles, Journal of

Integrative Bioinformatics, 4(2).

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 9)

PUBLICATIONS & REVIEWS CONTINUED:

14. Takimoto, C. and Kruzelock, R.P. (2007). Novel Agents and New Paradigms

for Colorectal Cancer: Beyond EGFR and VEGF. Colorectal Cancer:

Evidence-Based Chemotherapy Strategies. Current Clinical Oncology:

Humana Press,Totowa, NJ, 263-279.

15. Kruzelock, R.P. and Short W. (2007). Colorectal Cancer Therapeutics and

the Challenges of Applied Pharmacogenomics. Curr Probl Cancer. Sep-

Oct; 31(5), 315-66.

CONTRIBUTING EDITOR:

1. Mills, G.B., and Kruzelock, R.P. (1996). [Review of Winqvist et al.,

Loss of Heterozygosity for Chromosome 11 in Primary Human Breast

Tumors is Associated with Poor Survival After Metastasis, Cancer

Research, 55, 2660-2664] in Breast Diseases: A Year Book Quarterly,

7(1), 36-38.

2. Mills, G.B., and Kruzelock, R.P. (1996). [Review of Negrini et al.,

Definition and Refinement of Chromosome 11 Regions of Loss of

Heterozygosity in Breast Cancer: Identification of a New Region at

11q23.3, Cancer Research, 55, 3003-3007] in Breast Diseases: A Year

Book Quarterly, 7(1), 37-8.

3. Kruzelock, R.P., and Mills, G.B. (1997). [Review of Leek et al.,

Association of Macrophage Infiltration with Angiogenesis and Prognosis

in Invasive Breast Carcinoma, Cancer Research, 56, 4625-4629] in

Breast Diseases: A Year Book Quarterly, 8(2), 103-104.

4. Kruzelock, R.P., and Mills, G.B. (1997). [Review of Bieche et al., Two

Distinct Amplified Regions at 17q11-q21 Involved in Human Primary

Breast Cancer, Cancer Research, 56, 3886-3890] in Breast Diseases: A

Year Book Quarterly, 8(2), 100-101.

5. Kruzelock, R.P., and Mills, G.B. (1997). [Review of Davies, K., and

White M., Breakthrough: The Race to Find the Breast Cancer Gene: John

Wiley & Sons, Inc.] Oncology Times, XIX(6), 67.

PATENTS & DISCLOSURES:

1 Agan, B., Daum L., Hanson, E. H., Kruzelock, R.P., Lin, B., Rowley,

R., Santiago J., Seto, D., Stenger, D., Tibbetts, C., Vora, G.,

Walter E., and Wang, Z. (2005). Re-sequencing Pathogen Microarray.

Patent Application Number: 11/177,646.

SELECTED ABSTRACTS:

1. Kruzelock, R.P., Lago, D., Rabatin, V., and Ahern, F. (1987).

Prevalence of Concurrent Use of Anticholinergic Drugs in the

Elderly. Presented at the Gerontological Society of America

meeting in Washington D.C.

2. Kruzelock, R.P., and Barbato, G.F. (1990). Genotype Differences in

Catecholamine Concentrations in the Hypothalamus, Intramedial

Hyperstriatum Ventrale, and Optic Tectum of Newly Hatched Chicks.

Presented at the Poultry Science meeting in Blacksburg, VA.

3. Kruzelock, R.P., and Hansen, M.F., (1994). Mitotic Recombination

Mapping Localizes a Putative Tumor Suppressor on Chromosome 3q in

Osteosarcoma. Presented at the Molecular Genetics of Cancer

Symposium in Cold Spring Harbor, N.Y.

4. Kruzelock, R.P., Xu, F., Yu, Y., Mills, G.B., and Bast, R.C. (1998).

Microcell-mediated Chromosome Transfer Provides Functional Evidence

for an Ovarian Cancer Tumor Suppressor Gene on Chromosome 22.

Presented at the American Association for Cancer Research meeting

in New Orleans, LA.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 10)

SELECTED ABSTRACTS CONTINUED:

5. Wu, W-H., Frink, R., Cullen, R., Wick, M., Takimoto C.H., and

Kruzelock, R.P. (2005). Molecular Characterization of Preclinical

Models is a Critical Element for an Integrated Pharmacogenomics

Strategy. Presented at the AACR-NCI-EORTC International

Conference, Molecular Targets and. Cancer Therapeutics;

Philadelphia November 14 - 18, 2005.

6. Wu, W-H., Frink, R., Cullen, R., Wick, M., Takimoto C.H., and

Kruzelock, R.P. (2005). Comparison of 5-FU and Irinotecan Treated

HT-29 Cell Lines and Xenografts for Candidate Biomarkers Predictive

of Drug Response. Presented at the AACR-NCI-EORTC International

Conference, Molecular Targets and. Cancer Therapeutics;

Philadelphia November 14 - 18, 2005.

7. Kruzelock, R.P., Wu, W-H., Courage, J., Lovell1, A., Geller R., Ye,

K., Kwek, S., and Papadopoulos, K. (2006). Development of web-based

bioinformatics tools to reveal relationships between gene

expression, gene function and anticancer drug response. Presented

at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer

Therapeutics, Prague, Czech Republic, November 7-10, 2006.

6. Kruzelock, R.P., Wu, W-H., Courage, J., Short, W., Dominguez, C.,

Rodon, J., Tolcher, A., and Takimoto C.H. (2006). Development of a

300,000 Base Pair Custom Sequencing Microarray for Biomarker

Discovery and Anticancer Drug Development. Presented at the AACR-

NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics,

Prague, Czech Republic, November 7-10, 2006.

SELECT MILITARY BRIEFINGS & PRESENTATIONS:

1. Kruzelock, R.P., Xu, F., Yu, Y., Mills, G.B., and Bast, R.C. (1998).

Microcell Mediated Chromosome Transfer Provides Functional Evidence

for an Ovarian Cancer Tumor Suppressor Gene on Chromosome 22. Yale

University; New Haven, Connecticut

2. Kruzelock, R.P., (1999). Liquid Arrays: A Cheaper & More Reliable

Approach to Gene Expression Profiling. The University of Texas M.D.

Anderson Cancer Center; Houston, Texas.

3. Kruzelock, R.P., (2000). A Novel Assay for the Simultaneous

Identification of Thousands of Genes that Enhance or Suppress Tumor

Growth. Luminex Corporation; Austin, Texas.

4. Kruzelock, R.P., (2000). Critical Elements of a Comprehensive Cancer

Control Program. Department of Health; Boise Idaho & Department of

Health; Olympia, Washington.

5. Kruzelock, R.P., (2001). Microarray Technology in a Test Tube.

Houston, Texas Medical Center Mouse Research Consortium. Houston,

Texas.

6. Kruzelock, R.P., (2001). Solving the Mysteries of Cancer: New

Approaches in Functional Genomics. Virginia Bioinformatics Institute.

Virginia Polytechnic Institute and State University; Blacksburg,

Virginia

7. Kruzelock, R.P., (2001). Bringing Function to Functional Genomics.

Biogenetic Ventures; Spokane Washington.

8. Kruzelock, R.P., (2002). Detecting Exposure to Weapons of Mass

Destruction. Department of Defense Scientists Helping America

Conference. Naval Research Laboratories, Arlington, Virginia.

9. Kruzelock, R.P., (2002). Enabling Technologies for High-throughput

Vaccine Development. Institute for Research in Biomedicine Research

Consortium. Riva San Vitale, Switzerland.

10. Kruzelock, R.P., (2003). Advanced Integrated Technologies for

Improving Biodefense Capabilities. The United States Air Force Force

Protection Battlelab; Lackland Air Force Base, Texas.

11. Kruzelock, R.P., (2003). Developing Improved Strategies for Rapidly

Identifying Unknown Pathogens in an Epidemic Outbreak Scenario. The

University of Texas; Austin, Texas.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 11)

SELECT MILITARY BRIEFINGS & PRESENTATIONS CONTINUED:

12. Kruzelock, R.P., (2003). Integration of Genomic-based Technologies

for Pathogen Biosurveillance. DARPA Biological Warfare Defense

(BWD) Unconventional Pathogen Countermeasures (UPC) Principal

Investigator (PI) Conference. Galveston, Texas.

13. Kruzelock, R.P., (2007) Department of Defense Manufacturing

Opportunities Mapping [MOM] Database; A Pipeline for Government

Innovation. Society of Manufacturing Engineers EASTEC Conference.

Springfield, Massachusetts.

COURSES/LECTURES:

1. Kruzelock, R.P., and Amanda McWatters (April, 2002). Agricultural

Genetics - Animal & Poultry Sciences 4984. (Microarray Laboratory

and Lectures). Virginia Tech University, Blacksburg, VA

2. Kruzelock, R.P. (April, 2002). Biotechnology in a Global Society -

Biology 2404. (Lecture). Virginia Tech University, Blacksburg, VA

3. Kruzelock, R.P. (October, 2001). Advanced Topics in Veterinary

Medicine. (Lecture). Virginia Tech University, Blacksburg, VA

CANCER-RELATED INTERNET PROGRAMS & PUBLICATIONS:

1. Kruzelock, R.P., Claypool, C.K., Brinton, W., Dalrymple, J., Pustai,

L., Zinner, R., Levin, B., Hughes, P. (2000). National Cancer

Research & Education Foundation. Can I reduce my risk of ever getting

cancer? Houston, TX:

2. Kruzelock, R.P., Claypool, C.K., Brinton, W., Dalrymple, J., Pustai,

L., Zinner, R., Levin, B., Hughes, P. (2000). National Cancer

Research & Education Foundation. How do I detect cancer early enough

to do something about it? Houston, TX:

3. Kruzelock, R.P., Claypool, C.K., Brinton, W., Dalrymple, J., Pustai,

L., Zinner, R., Levin, B., Hughes, P. (2000). National Cancer

Research & Education Foundation. New Horizons in Cancer Research.

Houston, TX:

4. Kruzelock, R.P., Suraokar, M., Kruzelock, S.C., Kessman, J., Campbell,

C. (2000). National Cancer Research & Education Foundation. E-mail

HealthReminder Cancer Prevention Program. Houston, TX:

PERSONAL DATA:

? Citizenship: United States of America: Birthplace: Parma City, Ohio.

Security Clearance: SECRET

? Age 45, Married, five children (Ryan) 17 yrs.; (Alicia) 15 yrs.;

(Matthew) 11 yrs.; (Ashley) 8 yrs.; (Carol) 3 yr.

? Athletic and in excellent health (Enjoys family time, ranch work, fly

fishing, camping, hiking & reading).

9/91 to 6/04 BAR SEVEN

BAR RANCH

Waelder, Texas

? Raised family owned Registered Beefmasters until 1995 drought.

Then changed to a commercial operation.

? Experienced in ranch operation including genetics/management of

a registered Beefmaster herd.

RUSSELL P. KRUZELOCK Curriculum Vit e

(page 12)

PERSONAL DATA CONTINUED:

9/97 to 9/02 THE NATIONAL CANCER RESEARCH AND EDUCATION

FOUNDATION,

Houston, Texas

President

This foundation was established to develop human cancer prevention and

early detection initiatives as well as research programs currently directed

at defining human cancers on the basis of their molecular abnormalities.

My abbreviated responsibilities as the President and Executive Director of

this 501(c)3 corporation include:

? Preside over the business and affairs of the foundation.

? Assist in the preparation of the budget, help develop

fundraising plans, and make financial information

available to board members.

? Determine that the resolutions and directives of the board of

directors are carried into effect.

? Execute all authorized conveyances, contracts, deeds, mortgages,

bonds or other obligations in the name of the corporation.

? Convene and chair all regularly scheduled board meetings.

RUSSELL P. KRUZELOCK References

(page 13)

Jon R. Wiener, Ph.D

Associate Dean for Arts and Sciences (Math and Science)

Asheville-Buncombe Technical Community College

Elm Building, Asheville Campus

340 Victoria Rd

Asheville, NC 28801

Office: 828-***-**** Ext. 7650

abkppq@r.postjobfree.com

Dr. Kruzelock] is a natural leader, an excellent teacher, and

skilled not only with the biology required, but with the legal,

financial, and industrial arenas as well. The wide diversity of arenas

in science that he is outstanding at, including microbiology, human

biology, bioengineering, and chemistry, would, in my opinion, make him

the top candidate for this position. Simply put, I have seen many a young

up-and-coming scientist, and Rusty is in the top 1% of all I have known.

His combination of brilliance, communication skills, personal and

professional attributes, and professionalism, are peerless. I encourage

you in the strongest possible way to recruit this superb candidate."

Shawn M. deVillier

Senior Vice President of Investments.

Raymond James, Springfield, MA.

Mobile: 413-***-****

Email: abkppq@r.postjobfree.com

In September of 2010, companies throughout Massachusetts and

Connecticut came together in the spirit of cooperation and education to

realize the potential of the region's technological and manufacturing

base. This event would only have been possible through the efforts of

Rusty and his vision to assist the ideas that exist all around us.

Rusty's resume speaks volumes for his scientific capability, but his

leadership history represents his ability to "realize" what others often

only "wonder" about. Dr. Kruzelock will be infinitely valuable to any

project or idea that he applies himself"

Milind Suraokar, Ph.D.

Instructor, Thoracic Head & Neck Medical Oncology;

University of Texas MD Anderson Cancer Center, Houston, TX.

Mobile: 832-***-****

Email: abkppq@r.postjobfree.com

Rusty draws his research experience from a diverse background in

agriculture, genetics, molecular biology and microbiology. Having worked

side by side with Rusty at the bench, I can say that he is as fine of a

scientist that you will find anywhere. He is extremely collaborative by

nature with superlative grant writing skills. I know of no person with

equaled motivational skills, who negotiates equally well in the

laboratory, Pentagon halls, board room or class room. If you are looking

for a person who integrates easily and sparks 'life' into any program

with his ideas, creativity, and enthusiasm, then I recommend Dr. Rusty

Kruzelock to you in the highest possible terms."

Contact this candidate